89bio to Participate in the UBS Global Healthcare Conference

Rhea-AI Summary

89bio (Nasdaq: ETNB) has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 12:30 PM EST, along with one-on-one investor meetings. The presentation will be available via webcast on 89bio's investor website section, with replay access for approximately 30 days after the conference. 89bio is a clinical-stage biopharmaceutical company developing innovative therapies for liver and cardiometabolic diseases.

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.

The webcast of the presentation will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang 
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com

Media Contact: 
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com

FAQ

When is 89bio (ETNB) presenting at the UBS Global Healthcare Conference 2024?

89bio will present at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 12:30 PM EST.

How long will the replay of 89bio's (ETNB) UBS Conference presentation be available?

The webcast replay will be available for approximately 30 days following the conference.

What type of presentation will 89bio (ETNB) give at the UBS Healthcare Conference?

89bio's management will participate in a fireside chat and conduct one-on-one investor meetings.

Where can investors access 89bio's (ETNB) UBS Conference presentation?

The presentation webcast will be accessible through the investor section of 89bio's website.